Acerca de
NeuroCytonix Mexico was established in 2018 and operates a state-of-the-art clinical center in compliance with FDA guidelines for "Good Clinical Practice." Participants come from around the world for our experimental cerebral palsy treatment or to participate in research on our protocols’ efficacy at addressing other conditions like traumatic brain injury, long COVID brain fog, and stroke. If you or a loved one would like to participate in ongoing research or upcoming clinical trials, please contact us for more information.
Now treating children for cerebral palsy.
Contact us for more information.
About the NeuroCytonix Mexico facility
The NeuroCytonix Mexico center is located in Monterrey, the capital city of the state of Nuevo Leon, set in the spectacular Sierra Madre mountain range. Our clinic is in Latin America's safest municipality, San Pedro Garza Garcia, Nuevo Leon. The facility is well-equipped and designed to provide the best care and comfort possible while meeting the needs of participants who require specialized attention. Our primary mission is to explore innovative solutions to repair the brain and cure the incurable.
​
Our founder, Dr. J. Roberto Trujillo, was instrumental in creating the NeuroCytonix Mexico center. He trained and directed an outstanding clinical research team that successfully conducted our double-blind, randomized, placebo-controlled clinical trial for children with cerebral palsy. They continue to ensure that each new participant receives the highest level of care. We pride ourselves on providing personalized attention from a qualified team of specialist doctors, nurses, technicians, drivers, and professional regulatory and administrative staff to make your time with us a truly therapeutic experience.
What to know before you participate
Mexican regulatory agency COFEPRIS, the Mexican equivalent of the U.S. FDA, has approved our experimental cerebral palsy treatment for children after acknowledging the results of our rigorous clinical trial. Our experimental protocols are not yet FDA-approved, but we’re preparing to publish our results and seek FDA approval.
In alignment with that goal, we conduct all our research according to FDA clinical trial guidance. We’re also researching our protocols’ impacts on participants with other neurological disorders with promising results so far, and we expect to conduct formal clinical trials on these conditions soon.
NeuroCytonix Mexico, S.A. DE C.V.
Calzada San Pedro # 503. Col. del Valle.
San Pedro Garza García, Nuevo León. CP 66224